A-101 25% + A-101 32.5% + A-101 40% + A-101 Vehicle
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Seborrheic Keratosis (SK)
Conditions
Seborrheic Keratosis (SK)
Trial Timeline
Oct 22, 2013 → Feb 25, 2014
NCT ID
NCT01986920About A-101 25% + A-101 32.5% + A-101 40% + A-101 Vehicle
A-101 25% + A-101 32.5% + A-101 40% + A-101 Vehicle is a phase 1/2 stage product being developed by Aclaris Therapeutics for Seborrheic Keratosis (SK). The current trial status is completed. This product is registered under clinical trial identifier NCT01986920. Target conditions include Seborrheic Keratosis (SK).
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01986920 | Phase 1/2 | Completed |
Competing Products
15 competing products in Seborrheic Keratosis (SK)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elidel + Ketoconazole Cream | Novartis | Phase 2 | 52 |
| PF-07038124 + Placebo Ointment | Pfizer | Phase 2 | 51 |
| Ketoconazole | GSK plc | Approved | 84 |
| Azelaic Acid 15% Gel + Inactive 15% gel base | Bayer | Phase 2 | 49 |
| Ruxolitinib 1.5% Cream | Incyte | Phase 2 | 49 |
| Roflumilast Foam 0.3% + Vehicle foam | Arcutis Biotherapeutics | Phase 2 | 47 |
| Roflumilast Foam + Vehicle Foam | Arcutis Biotherapeutics | Phase 3 | 72 |
| ARQ-154 | Arcutis Biotherapeutics | Phase 2 | 47 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 Topical Solution | Aclaris Therapeutics | Approved | 77 |
| A-101 | Aclaris Therapeutics | Phase 2 | 44 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 69 |
| A-101 | Aclaris Therapeutics | Phase 2 | 44 |
| A-101 Vehicle + A-101 (40) Topical Solution + A-101 (32.5) Topical Solution | Aclaris Therapeutics | Phase 2 | 44 |